A Landmark Phase 3 Win for mRNA Cancer Vaccine
Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage clinical study.The experimental personalised cancer vaccine is being studied in melanoma, which accounts for about 1 per cent of skin cancers but causes the majority of deaths from the disease.
The Phase 3 trial involved more than 1,100 patients.For those participating in the trial, surgeons had already removed their tumors, and everyone had been treated with Keytruda, the standard immunotherapy.But some patients were also given the mRNA melanoma vaccine.
Merck and Moderna announced on Wednesday morning that a bespoke mRNA cancer vaccine, given alongside Merck’s blockbuster immunotherapy Keytruda after surgery, significantly reduced disease recurrence and metastasis in patients whose high-risk melanoma had just been surgically removed, compared to Keytruda alone.
The trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS).This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy.It is also the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma.
How Intismeran and Keytruda Work Together
Moderna’s mRNA vaccine — used in combination with Merck’s cancer immunotherapy drug Keytruda — is built from a patient’s own tumor, which has its own genetic sequence, so each dose is personalized.A computer algorithm then selects up to 34 of the resulting abnormal proteins most likely to attract an immune response, and those instructions are encoded into a custom-made mRNA vaccine for that individual patient.
The personalized mRNA vaccine and Keytruda are designed to deliver a one-two punch against cancer. Cancer can put a cloak of invisibility around itself so the immune system can’t see it, and the first punch is a drug called Keytruda, which removes the cloak, explained Dr. Jon LaPook.
Meanwhile, the patient’s cells read the mRNA and build a protein, breaking the messenger down. That protein then trains the immune system to learn to attack cancer cells. Think of it like giving a scent to a bloodhound. The vaccine gives the immune system the scent of melanoma so the immune system can hunt it down and kill it, LaPook said.
Expert Perspectives: A New Treatment Paradigm
Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia, said, Today’s results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint’ of a patient’s own tumour, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone.
Dr. Dean Y. Li, president, Merck Research Laboratories, said, By intervening earlier in the course of disease, when many cancers are considered most treatable, the goal of adjuvant therapy given after surgery is to increase the possibility of cure for more patients.
Stéphane Bancel, chief executive officer of Moderna, said, These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality.
It was an idea 10 years ago, it was a dream still three or four years ago, and now it feels like very much a reality, Moderna President Stephen Hoge told The Washington Post.
Moderna Stock Skyrockets 177% and MRNA Valuations Surge
Shares of Moderna soared 177 per cent in US trading overnight after the biotechnology company and Merck said their Phase 3 personalised vaccine trial met its endpoints. Following the development Moderna shares rose 177 per cent to hit a high of $174.38 apiece on NYSE.Moderna shares more than doubled, adding $44 billion in market value in a day.
Merck shares also climbed 12.60 per cent to $152.20. The huge move in Moderna stock is linked to the size of the two companies. Merck had a market value of around $333 billion before the jump, while Moderna’s market value was around $25 billion. This means the same positive news can create a much bigger percentage move for Moderna.
The positive Phase 3 data give investors evidence that the company’s personalized mRNA cancer vaccine technology can work in a late-stage clinical trial. Analysts said Moderna’s valuation before Wednesday’s jump already reflected hopes that the personalized cancer vaccine could eventually work against multiple types of cancer, not just melanoma.
While the melanoma data drove Wednesday’s rally, Moderna’s underlying financials tell a more measured story. Moderna reported second-quarter 2026 revenue of $145 million, up marginally from $142 million a year earlier, as higher UK vaccine deliveries and stand-ready manufacturing revenue offset weaker COVID sales in the US and South America.The company’s net loss came in at $782 million, narrower than the $825 million loss in Q2 2025.
Moderna co-founder Robert Langer has returned to billionaire status.Robert Langer, who is believed to retain roughly a 3% stake in Moderna, saw the estimated value of his holding rise to about $1.7 billion by Wednesday, from around $730 million a day earlier.Fellow Moderna co-founder Noubar Afeyan saw his estimated fortune increase by about $184 million to $2.1 billion.Moderna chief executive Stéphane Bancel’s wealth rose by roughly $2.5 billion to $4.8 billion.
Merck Stock, Keytruda, and the 2028 Patent Cliff
The trial could also prove important for Merck as it looks to develop new growth opportunities around Keytruda, its best-selling cancer treatment, amid an approaching patent expiry.Keytruda’s US patent protection expires in 2028 , opening the largest revenue cliff in pharmaceutical history, roughly $30 billion in annual sales for Merck to competition from biosimilar manufacturers.
A therapy that requires tumour sequencing, computational neoantigen prediction, mRNA synthesis and cold-chain distribution — all inside a six-to-eight week window per patient — carries a cost structure that, by every industry estimate, sits well into six figures in US dollars per course of treatment.
Merck and Moderna are studying the vaccine in several trials across other tumors, such as non-small cell lung cancer, bladder cancer and renal cell carcinoma. The companies plan to present the study results at an upcoming international medical meeting. That opens the door for the Food and Drug Administration to potentially approve the first mRNA-based cancer treatment, in what would be a landmark moment for the fast-emerging field.
Sources Quoted
- The Washington Post: Quoted for details on customized mRNA vaccine algorithms and FDA implications.
- Hindustan Times: Quoted for clinical trial data endpoints, Keytruda combination, and the 2028 patent cliff context.
- Financial Express: Quoted for stock data, market value milestones ($44B added), primary endpoints (RFS/DMFS), and Q2 2026 financial earnings.
- Business Today: Quoted for precise stock percentage jumps (177% and 12.60%) and direct expert quotes from Prof. Georgina Long, Dr. Dean Y. Li, and Stéphane Bancel.
- CBS News: Quoted for analogies explaining the mechanism of action via Dr. Jon LaPook.
- LiveMint: Quoted for the wealth impact on Moderna executives and founders.
- Al Jazeera / AP News: Quoted for overarching headline summaries regarding Intismeran.
Leo Falsafi is a digital marketing veteran and senior journalist at Virlan.co, where he covers the intersection of digital marketing, gaming, and breaking US trending news. With nearly two decades of hands-on experience in SEO and digital strategy, Leo has consulted for and scaled hundreds of companies. His deep industry roots allow him to deliver sharp, fact-checked insights and analysis on the trends shaping today’s digital landscape.
